1
项与 CLL1 CAR-NK cells(Hangzhou Qihangene Biotech) 相关的临床试验Clinical Study to Evaluate the Safety and Efficacy of iPSC NK Cells Targeting CLL1 in Patients With Relapsed/Refractory AML
This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 target CAR iPSC NK cells in patients with relapsed/refractory AML
100 项与 CLL1 CAR-NK cells(Hangzhou Qihangene Biotech) 相关的临床结果
100 项与 CLL1 CAR-NK cells(Hangzhou Qihangene Biotech) 相关的转化医学
100 项与 CLL1 CAR-NK cells(Hangzhou Qihangene Biotech) 相关的专利(医药)
100 项与 CLL1 CAR-NK cells(Hangzhou Qihangene Biotech) 相关的药物交易